Fulgent Genetics Inc
Company Profile
Business description
Fulgent Genetics Inc is a technology company that focuses on genetic testing to provide physicians with clinically actionable diagnostic information. The company is engaged in laboratory services business and a therapeutic development business. The laboratory services business which generates key revenue includes, technical laboratory services and professional interpretation of laboratory results by licensed physicians. Its therapeutic development business is focused on developing drug candidates for treating a broad range of cancers. The geographical segments are the United States, which generates the vast majority of the revenue; and Foreign.
Contact
4399 Santa Anita Avenue
El MonteCA91731
USAT: +1 626 350-0537
Sector
Healthcare
Stock type
Defensive
Industry
Diagnostics & Research
Fiscal Year End
31 December 2025
Employees
1,313
Stocks News & Analysis
stocks
Tesla’s stock is in trouble, but this fund manager sees a comeback in 2026
stocks
Cheap ASX energy play boasts strong cash flows and balance sheet
stocks
Market overreacts to earnings miss from moated ASX retailer
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,245.00 | 66.30 | -0.71% |
| CAC 40 | 7,843.04 | 126.65 | -1.59% |
| DAX 40 | 24,273.12 | 89.97 | -0.37% |
| Dow JONES (US) | 45,282.47 | 349.27 | -0.77% |
| FTSE 100 | 9,321.40 | 12.20 | 0.13% |
| HKSE | 25,829.91 | 490.77 | 1.94% |
| NASDAQ | 21,449.29 | 47.24 | -0.22% |
| Nikkei 225 | 42,807.82 | 174.53 | 0.41% |
| NZX 50 Index | 13,072.36 | 7.14 | -0.05% |
| S&P 500 | 6,439.32 | 27.59 | -0.43% |
| S&P/ASX 200 | 8,972.40 | 71.70 | -0.79% |
| SSE Composite Index | 3,883.56 | 57.80 | 1.51% |